Eyeworld

INDICATION DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis. WARNINGS AND PRECAUTIONS Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment. Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. ADVERSE REACTIONS The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%). The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%). Please see brief summary of full Prescribing Information on adjacent page. © 2019 Ocular Therapeutix, Inc. All rights reserved. DEXTENZA is a registered trademark of Ocular Therapeutix, Inc. PP-US-DX-0193 References: 1. Sawhney AS et al, inventors; Incept LLC, assignee. US patent 8,409,606 B2. April 2, 2013. 2. DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix, Inc; 2019. 3. Walters T et al. J Clin Exp Ophthalmol. 2016;7(4):1-11. 4. Tyson SL et al. J Cataract Refract Surg. 2019;45(2):204-212. *73.6% of physicians in Study 1, 76.4% in Study 2, and 79.6% in Study 3 rated DEXTENZA as easy to insert. • Resorbable, so no need for removal 2 • Insert can be removed via saline irrigation or manual expression, if necessary 2 • Physicians rated DEXTENZA as easy to insert 3,4 * • Designed to deliver a tapered dose 1 • Contains fluorescein for visualization 2 • No additional components or assembly required 2 DEXTENZA IS AN ADVANCEMENT IN STEROID TREATMENT LEARN MORE AT DEXTENZA.COM The only sustained-release steroid approved for the treatment of inflammation and pain following ophthalmic surgery NOW USE UNIQUE BILLING CODE J1096 BIG TIME INNOVATION 1 THE FIRST AND ONLY OPHTHALMIC STEROID INSERT

• Blank Page
• Blank Page (1)